We are live on ! Find out more
AUTL

Autolus Therapeutics
AUTL

69 hedge funds and large institutions have $169M invested in Autolus Therapeutics in 2021 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 13 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

69% more repeat investments, than reductions

Existing positions increased: 22 | Existing positions reduced: 13

35% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 17

31% more capital invested

Capital invested by funds: $129M → $169M (+$39.9M)

10% more funds holding

Funds holding: 63 → 69 (+6)

4.29% more ownership

Funds ownership: 33.82% → 38.11% (+4.3%)

Holders
69
Holders Change
+6
Holders Change %
+9.52%
% of All Funds
1.2%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
22
Reduced
13
Closed
17
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$16.9M
2
FM
Frazier Management
Washington
+$14.2M
3
NCM
Nantahala Capital Management
Connecticut
+$11.1M
4
Goldman Sachs
Goldman Sachs
New York
+$3.97M
5
SCM
Sio Capital Management
New York
+$3.67M

Top Sellers

Rank Fund Capital Flow
1
Capital International Investors
Capital International Investors
California
-$13M
2
DM
Deerfield Management
New York
-$12.3M
3
OM
Opaleye Management
Massachusetts
-$12.1M
4
BBA
Baker Bros. Advisors
New York
-$2.65M
5
BlackRock
BlackRock
New York
-$1.51M
Name Holding Trade Value Shares
Change 		Change in
Stake
EAM
26
Erste Asset Management
Austria
$785K – – –
MA
27
MYDA Advisors
New York
$564K +$528K +85,000 New
SFI
28
Susquehanna Fundamental Investments
Pennsylvania
$418K +$391K +62,950 New
JGC
29
J. Goldman & Co
New York
$391K +$365K +58,870 New
RCM
30
Regency Capital Management
Hawaii
$378K -$24.8K -4,000 -7%
BlackRock
31
BlackRock
New York
$364K -$1.51M -242,764 -82%
HJIM
32
Henry James International Management
New York
$359K – – –
Geode Capital Management
33
Geode Capital Management
Massachusetts
$319K +$201K +32,379 +205%
JF
34
Jump Financial
Illinois
$314K +$170K +27,460 +139%
RE
35
RBC Europe
United Kingdom
$313K – – –
TI
36
Trexquant Investment
Connecticut
$275K +$257K +41,372 New
HF
37
HRT Financial
New York
$227K +$145K +23,417 +215%
D.E. Shaw & Co
38
D.E. Shaw & Co
New York
$216K +$202K +32,500 New
Jane Street
39
Jane Street
New York
$196K +$184K +29,588 New
New York State Common Retirement Fund
40
New York State Common Retirement Fund
New York
$180K -$45K -7,250 -21%
DTL
41
Dynamic Technology Lab
Singapore
$164K +$154K +24,786 New
State Street
42
State Street
Massachusetts
$146K -$3.2K -515 -2%
Legal & General Group
43
Legal & General Group
United Kingdom
$142K +$64.8K +10,446 +96%
CSS
44
Cubist Systematic Strategies
Connecticut
$134K -$35.6K -5,730 -22%
UBS Group
45
UBS Group
Switzerland
$107K -$16.3K -2,633 -14%
XT
46
XTX Topco
Cayman Islands
$101K +$94.9K +15,286 New
Deutsche Bank
47
Deutsche Bank
Germany
$99K +$92.3K +14,876 New
WMSA
48
Weiss Multi-Strategy Advisers
New York
$96K +$3.2K +516 +4%
Tudor Investment Corp
49
Tudor Investment Corp
Connecticut
$93K +$86.8K +13,991 New
APA
50
American Portfolios Advisors
New York
$86.7K +$15.2K +2,450 +23%
1
2
3 4

AUTL Hedge Fund Activity: Q2 2021 in Review

69 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q2 2021, worth a combined $169M — up 31% from $129M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new AUTL positions and 17 closed out — a net gain of 6 holders — while 22 added to existing stakes and 13 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $16.9M. The largest seller was Capital International Investors, exiting entirely with an estimated $13M sold.

  • 69 institutional investors held Autolus Therapeutics (AUTL) as of Q2 2021, up from 63 in Q1 2021.
  • Funds reported $169M of Autolus Therapeutics stock for Q2 2021, up 31% quarter-over-quarter.
  • 23 funds opened new Autolus Therapeutics positions in Q2 2021 and 17 closed out, a net change of +6 holders.
  • The largest Autolus Therapeutics buyer in Q2 2021 was Citadel Advisors, an estimated $16.9M added.
  • The largest Autolus Therapeutics seller in Q2 2021 was Capital International Investors, an estimated $13M sold.

Based on aggregated 13F filings for Q2 2021.